Table 2.
Patient Demographics: Validation Cohort
| Parameter | Total (n = 495) | SSRI/SNRI+ (n = 50) | SSRI− (n = 445) | P |
|---|---|---|---|---|
| Median (Range), n (%) | Median (Range), n (%) | Median (Range), n (%) | ||
| Gender | 0.445 | |||
| Male | 258 (52.1%) | 23 (46.0%) | 235 (52.8%) | |
| Female | 237 (47.9%) | 27 (52.9%) | 210 (47.3%) | |
| Age (years) | 62 (18‐84) | 60 (28‐79) | 62 (18‐84) | 0.628 |
| Hepatic resection | ||||
| Major | 495 (100%) | 50 (100%) | 444 (100%) | |
| Tumor type | 0.180 | |||
| CRLM | 188 (38.0%) | 22 (44.0%) | 166 (37.3%) | |
| HCC | 122 (24.6%) | 15 (30.0%) | 107 (24.1%) | |
| CCC | 185 (37.4%) | 13 (26.0%) | 172 (38.7%) | |
| Preoperative parameters | ||||
| SB (mg/dL) | 0.60 (0.10‐25.5) | 0.50 (0.10‐7.70) | 0.60 (0.10‐25.5) | 0.003 |
| INR | 1.0 (0.8‐4.0) | 1.0 (0.8‐4.0) | 1.0 (0.8‐2.0) | 0.694 |
| ALT (U/L) | 51 (10‐2420) | 40 (10‐301) | 52 (13‐2420) | 0.0.71 |
| Albumin (g/L) | 41 (23‐45) | 41.0 (31‐48) | 42.0 (21‐54) | 0.665 |
| Platelets (G7l) | 244 (29‐969) | 255 (78‐649) | 243 (29‐969) | 0.234 |
| Morbidity | ||||
| None | 151 (33.0%) | 10 (20.0%) | 141 (31.7%) | |
| Any grade | 307 (67.0%) | 39 (78.0%) | 268 (60.2%) | 0.048 |
| Severe | 95 (20.7%) | 17 (34.0%) | 78 (17.5%) | 0.011 |
| LD ISGLS | ||||
| No LD | 410 (82.8%) | 37 (74.0%) | 373 (84.0%) | |
| All grades | 85 (17.2%) | 13 (26.0%) | 71 (16.0%) | 0.040 |
| Grade C | 25 (5.1%) | 5 (10.0%) | 20 (4.5%) | 0.102 |
Bold indicates significance.
Abbreviation: ALT, alanine aminotransferase.